Anas Zayad

[Anas Zayad @AnasZayad]

🔗 https://t.co/KUakwfSsKx

#MultipleMyeloma #mmsm #USMIRC @USMIRCNEWS @MM_Hub @Abdallah81MD

[Anas Zayad @AnasZayad]

DPd or DKd in relapsed myeloma? Efficacy may be similar—but toxicity differs.

Our real-world study of 399 patients:
• mPFS: 15 vs 12 mo (p=0.20)
 • Grade ≥3 neutropenia: 36% vs 23%
 • CV events: 18% vs 29%

Distinct toxicity profiles may guide regimen selection.

[Anas Zayad @AnasZayad]

Who is driving clinical trial funding?
Do multinational trials truly deliver global participation?

Our 20-year analysis of 845 clinical trials reveals the answers.

Link: https://t.co/HuCaJqcajR
@MDPIOpenAccess @USMIRCNEWS @Abdallah81MD
#CancerResearch #Oncology #Myeloma

[Anas Zayad @AnasZayad]

The future of multiple myeloma treatment is shaped by clinical trials but where is that research happening?

Is innovation concentrated in just a handful of countries?
Which countries are leading multiple myeloma clinical research?
Where are early and late phase trials conducted?

[Al-Ola A Abdallah MD (USMIRC) @Abdallah81MD]

🧵🚨 Newly Diagnosed High-Risk Myeloma: Does “Double-Hit” Still Predict Worse Outcomes After ASCT?

1/In our multicenter real-world study of 154 transplant-eligible patients with high-risk MM, we compared:

🔹 Single-hit HRMM = 1 high-risk cytogenetic abnormality
🔹 Double-hit HRMM = ≥2 high-risk cytogenetic abnormalities

#MMSM #myeloma #MedEd #medtwitter #USMIRC @US_HMC @MedwatchKate @OncoAlert @Larvol @USMIRCNEWS @CurrentOncology @KUcancercenter

[Anas Zayad @AnasZayad]

@Abdallah81MD @AtrashShebli @USMIRCNEWS @MDPIOpenAccess @CurrentOncology

[Anas Zayad @AnasZayad]

New Publication: Double-hit vs single-hit high-risk NDMM in transplant-eligible patients (n=154). Higher post-ASCT ORR in single-hit (97% vs 82% , p=0.006), but no difference in PFS (36 vs 31 mo) or OS (103 vs 94 mo).

Would value your thoughts.
https://t.co/vgu4PabTIx

[OncoDaily @oncodaily]

Outstanding Young Leaders Joining the USMIRC Community in 2025 - @Abdallah81MD

@AnasZayad

https://t.co/gfjWpvSQ3j

#Cancer #Oncology #OncoDaily #Health #Medicine @CancerWorldmag

[Al-Ola A Abdallah MD (USMIRC) @Abdallah81MD]

🧵🧵 Daratumumab-based triplets in RRMM: Real-world DPd vs DKd outcomes @USMIRCNEWS #USMIRC

1/ 💉 Study design: Multicenter retrospective analysis (n=399) of RRMM patients:
•DPd = Dara + Pomalidomide + Dex (n=295)
•DKd = Dara + Carfilzomib + Dex (n=104)
Goal 👉 compare efficacy & safety outside trial setting.

#ICE_T #mmsm #MedEd #myeloma #MedTwitter #USMIRC @USMIRCNEWS @OncoAlert #سرطان_الدم #المايلوما

[USMIRC News @USMIRCNEWS]

Efficacy and Safety of Daratumumab-Based Triplet Regimens in Relapsed Multiple Myeloma
By @AnasZayad @Abdallah81MD @mumairmushtaq @AtrashShebli @NausheenAhmedMD @KUcancercenter #mmsm #myeloma #MedTwitter #MedEd #USMIRC

https://t.co/KJMqK7Bs1e

[USMIRC News @USMIRCNEWS]

Now August issue from @USMIRCNEWS by @Abdallah81MD @AtrashShebli @AnasZayad

#ICE_T #mmsm #MedEd #myeloma #MedTwitter #USMIRC @USMIRCNEWS

https://t.co/IV7TQsv9kY !

[Anas Zayad @AnasZayad]

Happy to be part of this case report. Grateful to Dr. @FaizAnwerMD1 for his support.

[Faiz Anwer MD @FaizAnwerMD1]

A unique toxicity linked with MOA with talquetamab use published by our team in BMJ Case Reports.

https://t.co/f2nHFvygdd

[Al-Ola A Abdallah MD (USMIRC) @Abdallah81MD]

Huge congratulations to @hiragss, @j_snyder0132, and @AnasZayad for winning the USMIRC Medal awards! 🎉
#USMIRC @USMIRCNEWS @ASH_hematology #mmsm #MedTwitter @OncoAlert

[USMIRC News @USMIRCNEWS]

🎉 Huge congratulations to our amazing colleagues for winning the USMIRC Medal Awards for 2024! What an incredible achievement! 🏆 Let's celebrate their hard work and dedication! 🎊@mumairmushtaq @j_snyder0132 @AnasZayad @hiragss @mshahzadmd #USMIRC @mrf_org @USMIRCNEWS

[USMIRC News @USMIRCNEWS]

🧵 ASH abstracts via #USMIRC group (Myeloma subdivision): 2288 The Impact of Financial Support on the Development of Clinical Research in Multiple Myeloma: An in-Depth Analysis (1980-2024)
Presents by @AnasZayad @AtrashShebli
#mmsm #ASH2024 #MedTwitter
https://t.co/Hzd0SGyVwH

[Anas Zayad @AnasZayad]

@SmadiZina Best Subgroup 🔥🔥

[Anas Zayad @AnasZayad]

@mohaaaannad مبارك يا رب ❤️❤️❤️🔥

[Anas Zayad @AnasZayad]

@Yazz_i7 الف مبروك 🎉❤️

[Anas Zayad @AnasZayad]

@MajedFt الف مبروك حكيم 🌹

[Anas Zayad @AnasZayad]

@ZeyadAlzoubi99 استعن بالله ان شاء الله بتقدم كويس وبتكون هالايام ذكرى لا غير